You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer

Citation Tools

Article menu

Download PDFPDF

Oral Featured Posters
OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Backes F, Fowler J, Copeland L, et al
OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer
International Journal of Gynecologic Cancer 2021;31:A13-A14.